Gut hormones (GLP-1, PYY, oxyntomodulin, amylin, PP, CCK) represent the most tractable peripheral targets for obesity drugs, with GLP-1 agonists and PYY analogs leading the clinical pipeline.
Key findingPeripheral gut hormone-based obesity drug development focuses on GLP-1 agonists (most advanced), PYY analogs, oxyntomodulin, amylin analogs, and PP as
What the researchers found
Peripheral gut hormone-based obesity drug development focuses on GLP-1 agonists (most advanced), PYY analogs, oxyntomodulin, amylin analogs, and PP as practical anti-obesity drug targets with established physiological rationale and clinical precedent.
Why it matters
Relevant for glp-1, neuropeptides, weight-loss, clinical-trials.
How the study worked
review study on glp-1, neuropeptides.
What this study cannot tell us
See abstract.
How to read the evidence
moderate evidence.
When this study was published
Published in 2004.
The bigger picture
Advances peptide therapeutics research.
Questions still open
- Further research needed.
- Clinical translation to evaluate.
Common questions
What was studied?
What was found?
Read the original research
Gut hormones as peripheral anti obesity targets.
Current drug targets. CNS and neurological disorders, 3(5), 379-88
Citation
Small, Caroline J; Bloom, Stephen R. (2004). Gut hormones as peripheral anti obesity targets.. Current drug targets. CNS and neurological disorders, 3(5), 379-88.